Reporting from the ESMO Congress 2021, Richard Cathomas gives an overview of important study results covering metastatic prostate cancer. He begins by covering the informative findings from the ARCHES study testing enzalutamide plus ADT in hormone-sensitive prostate cancer. Then he comments on results from the castration resistant setting in the COSMIC-021 trial testing a combination of atezolizumab + cabozantinib, and finally, discusses results from the SAKK 08/16 study about darolutamide maintenance therapy.
- LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): primary analysis of cohort 6 of the COSMIC-021 study - Dr Neeraj Agarwal, US
- LBA25 - Overall survival (OS) from ARCHES: final analysis of the phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) - Dr Andrew Armstrong, US
- LBA26 - Darolutamide maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents and subsequent treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial (SAKK 08/16) - Dr Richard Cathomas, CH
This video was supported with an educational grant from Janssen Pharmaceutical companies of Johnson & Johnson.
The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.